EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Low HIV drug resistance prevalence among recently diagnosed HIV‐positive men who have sex with men in a setting of high PrEP use

Jonathan M King iD, Francesca Di Giallonardo iD, Ansari Shaik, Skye McGregor, Julie Yuek Kee Yeung, Tharshini Sivaruban, Frederick J Lee, Philip Cunningham, Dominic E Dwyer, Steven J Nigro, Andrew E Grulich, Anthony D Kelleher

Journal of the International AIDS Society · 2024

DOI: 10.1002/jia2.26308 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the International AIDS Society, 2024. Verfasst von Jonathan M King und 11 weiteren Autor:innen. Beteiligte Einrichtung: The Kirby Institute, University of New South Wales, Sydney, Australia. Hauptthemen laut MEDLINE: Pre-Exposure Prophylaxis, HIV Infections, Drug Resistance, Viral, Anti-HIV Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Future Fund, Genomics Health Futures Mission-Pathogens Genomics Grant Opportunity.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

New South Wales (NSW) has one of the world's highest uptake rates of HIV pre‐exposure prophylaxis (PrEP). This uptake has been credited with sharp declines in HIV transmission, particularly among Australian‐born gay and bisexual men. Concerns have been raised around the potential for the emergence of tenofovir (TFV) and XTC (lamivudine/emtricitabine) resistance in settings of high PrEP use. Such an emergence could also increase treatment failure and associated clinical outcomes among people living with HIV (PLHIV). Despite low levels of nucleoside reverse‐transcriptase inhibitor (NRTI) resistance relating to PrEP use in clinical settings, there are few published studies describing the prevalence of NRTI resistance among people newly diagnosed with HIV in a setting of high PrEP use.

Methods

Using HIV antiretroviral drug resistance data linked to NSW HIV notifications records of people diagnosed from 1 January 2015 to 31 December 2021 and with HIV attributed to male‐to‐male sex, we described trends in TFV and XTC resistance. Resistance was identified using the Stanford HIV Drug Resistance genotypic resistance interpretation system. To focus on transmitted drug resistance, resistance prevalence estimates were generated using sequences taken less than 3 months post‐HIV diagnosis. These estimates were stratified by timing of sequencing relative to the date of diagnosis, year of sequencing, birthplace, likely place of HIV acquisition, and stage of HIV at diagnosis.

Results

Among 1119 diagnoses linked to HIV genomes sequenced less than 3 months following diagnosis, overall XTC resistance prevalence was 1.3%. Between 2015 and 2021, XTC resistance fluctuated between 0.5% to 2.9% and was 1.0% in 2021. No TFV resistance was found over the study period in any of the sequences analysed. Higher XTC resistance prevalence was observed among people with newly acquired HIV (evidence of HIV acquisition in the 12 months prior to diagnosis; 2.9%, p = 0.008).

Conclusions

In this Australian setting, TFV and XTC resistance prevalence in new HIV diagnoses remained low. Our findings offer further evidence for the safe scale‐up of PrEP in high‐income settings, without jeopardizing the treatment of those living with HIV.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pre-Exposure ProphylaxisHIV InfectionsDrug Resistance, ViralAnti-HIV AgentsHomosexuality, MaleHumansMaleAdultPrevalenceNew South WalesMiddle AgedYoung AdultTenofovirEmtricitabineAdolescentLamivudineHIV-1

Stichwörter der Autor:innen

ARVHIV preventiondrug resistancemen who have sex with menpre‐exposure prophylaxistreatment

Substanzen

Anti-HIV AgentsTenofovirEmtricitabineLamivudine

Autor:innen und Institutionen

  • The Kirby Institute, University of New South Wales, Sydney, Australia.
  • New South Wales State Reference Laboratory - HIV/AIDS, St Vincent's Hospital, Sydney, Australia.
  • New South Wales Health Pathology-ICPMR, Westmead Hospital, Westmead, Australia.
  • New South Wales Health Pathology-RPA, Royal Prince Alfred Hospital, Camperdown, Australia.
  • Department of Clinical Immunology and Allergy, Royal Prince Alfred Hospital, Camperdown, Australia.
  • Health Protection NSW, NSW Ministry of Health, Sydney, Australia.

ORCID-Profile: Jonathan M King, Francesca Di Giallonardo

Förderung

  • Medical Research Future Fund
  • Genomics Health Futures Mission-Pathogens Genomics Grant Opportunity

Zitieren

APA

King, J. M., Giallonardo, F. D., Shaik, A., McGregor, S., Yeung, J. Y. K., Sivaruban, T., Lee, F. J., Cunningham, P., Dwyer, D. E., Nigro, S. J., Grulich, A. E., & Kelleher, A. D. (2024). Low HIV drug resistance prevalence among recently diagnosed HIV‐positive men who have sex with men in a setting of high PrEP use. Journal of the International AIDS Society. https://doi.org/10.1002/jia2.26308

Vancouver

King JM, Giallonardo FD, Shaik A, McGregor S, Yeung JYK, Sivaruban T, et al. Low HIV drug resistance prevalence among recently diagnosed HIV‐positive men who have sex with men in a setting of high PrEP use. Journal of the International AIDS Society. 2024. doi:10.1002/jia2.26308

BibTeX
@article{King2024,
  author = {King, Jonathan M and Giallonardo, Francesca Di and Shaik, Ansari and McGregor, Skye and Yeung, Julie Yuek Kee and Sivaruban, Tharshini and Lee, Frederick J and Cunningham, Philip and Dwyer, Dominic E and Nigro, Steven J and Grulich, Andrew E and Kelleher, Anthony D},
  title = {Low HIV drug resistance prevalence among recently diagnosed HIV‐positive men who have sex with men in a setting of high PrEP use},
  journal = {Journal of the International AIDS Society},
  year = {2024},
  doi = {10.1002/jia2.26308}
}
Kostenlos starten →